This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Fecal Incontinence
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
-
UC San Diego Health, La Jolla, California, United States, 92122
UC Irvine Medical Center, Orange, California, United States, 92868
Prestige Medical Group, Tustin, California, United States, 92780
University of Florida Shands Hospital, Gainesville, Florida, United States, 32610
Healthcare Clinical Data, Inc., Miami, Florida, United States, 33161
Orlando Health Colon & Rectal Institute, Orlando, Florida, United States, 32806
USF Health South Tampa Center for Advanced Healthcare, Tampa, Florida, United States, 33606
Colorectal Wellness Center, Fayetteville, Georgia, United States, 30214
University of Illinois, Chicago, Illinois, United States, 60612
Franciscan Health Indianapolis, Indianapolis, Indiana, United States, 46237
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
No
Cook MyoSite,
Ron Jankowski, PhD, STUDY_DIRECTOR, Cook Myosite, Inc.
2027-09